SI3079691T1 - Farmacevtski sestavek, ki vsebuje dantrolen kot rianodin receptor antagonist za olajšanje celjenja ran - Google Patents
Farmacevtski sestavek, ki vsebuje dantrolen kot rianodin receptor antagonist za olajšanje celjenja ranInfo
- Publication number
- SI3079691T1 SI3079691T1 SI201431665T SI201431665T SI3079691T1 SI 3079691 T1 SI3079691 T1 SI 3079691T1 SI 201431665 T SI201431665 T SI 201431665T SI 201431665 T SI201431665 T SI 201431665T SI 3079691 T1 SI3079691 T1 SI 3079691T1
- Authority
- SI
- Slovenia
- Prior art keywords
- dantrolene
- pharmaceutical composition
- wound healing
- receptor antagonist
- ryanodine receptor
- Prior art date
Links
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 title 1
- 229960001987 dantrolene Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 102000042094 ryanodine receptor (TC 1.A.3.1) family Human genes 0.000 title 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 title 1
- 230000029663 wound healing Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1300720A HUP1300720A2 (hu) | 2013-12-12 | 2013-12-12 | Gyógyászati készítmények sebgyógyulás elõsegítésére |
| EP14837102.4A EP3079691B1 (en) | 2013-12-12 | 2014-12-12 | Pharmaceutical composition comprising dantrolene as ryanodine receptor antagonist for facilitating wound healing |
| PCT/HU2014/000124 WO2015087097A2 (en) | 2013-12-12 | 2014-12-12 | Pharmaceutical compositions for facilitating wound healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3079691T1 true SI3079691T1 (sl) | 2020-12-31 |
Family
ID=89991355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201431665T SI3079691T1 (sl) | 2013-12-12 | 2014-12-12 | Farmacevtski sestavek, ki vsebuje dantrolen kot rianodin receptor antagonist za olajšanje celjenja ran |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9757360B2 (sl) |
| EP (1) | EP3079691B1 (sl) |
| CN (1) | CN105992586A (sl) |
| HU (2) | HUP1300720A2 (sl) |
| SI (1) | SI3079691T1 (sl) |
| WO (1) | WO2015087097A2 (sl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA127738C2 (uk) | 2017-10-20 | 2023-12-20 | Іґл Рісерч Лебс Лімітед | Проліки дантролену і способи їх застосування |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4049650A (en) * | 1976-10-18 | 1977-09-20 | Morton-Norwich Products, Inc. | 1-[[[5-(Substituted phenyl)-2-oxazolyl]methylene]amino]-2,4-imidazolidinediones |
| US5132119A (en) * | 1989-07-31 | 1992-07-21 | Massachusetts Institute Of Technology | Treatment of hypertrophic wound healing disorders with calcium channel blockers |
| JP2007308403A (ja) | 2006-05-17 | 2007-11-29 | Kenji Yoshida | 皮膚外用剤 |
| US20090306163A1 (en) | 2008-06-10 | 2009-12-10 | Pamela Renee Lipkin | Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling |
| JP2011250728A (ja) | 2010-06-01 | 2011-12-15 | Shiseido Co Ltd | リアノジン受容体を用いた皮膚バリアー機能回復促進物質のスクリーニング方法 |
| WO2012037519A2 (en) | 2010-09-16 | 2012-03-22 | University Of Miami | Acceleration of wound healing by growth hormone releasing hormone and its agonists |
-
2013
- 2013-12-12 HU HU1300720A patent/HUP1300720A2/hu unknown
-
2014
- 2014-12-12 US US15/103,374 patent/US9757360B2/en active Active
- 2014-12-12 HU HUE14837102A patent/HUE050861T2/hu unknown
- 2014-12-12 SI SI201431665T patent/SI3079691T1/sl unknown
- 2014-12-12 CN CN201480075392.6A patent/CN105992586A/zh active Pending
- 2014-12-12 EP EP14837102.4A patent/EP3079691B1/en active Active
- 2014-12-12 WO PCT/HU2014/000124 patent/WO2015087097A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US9757360B2 (en) | 2017-09-12 |
| WO2015087097A3 (en) | 2015-09-11 |
| CN105992586A (zh) | 2016-10-05 |
| WO2015087097A2 (en) | 2015-06-18 |
| HUP1300720A2 (hu) | 2015-06-29 |
| US20160303085A1 (en) | 2016-10-20 |
| EP3079691B1 (en) | 2020-07-01 |
| EP3079691A2 (en) | 2016-10-19 |
| HUE050861T2 (hu) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE045982T2 (hu) | S-Ketamin-hidroklorid gyógyászati kompozíció | |
| HK1213182A1 (zh) | 外用藥物組合物 | |
| ZA201401683B (en) | Pharmaceutical compositions for rectal administration | |
| IL268718B (en) | Opioid receptor modulator dosage formulation | |
| HK1199878A1 (en) | Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists | |
| EP2968698A4 (en) | COMPOUNDS AND COMPOSITIONS FOR RELEASE OF MEDICAMENT | |
| IL240019A0 (en) | Estrogen receptor inhibitors | |
| IL244356A0 (en) | Formulations for cgrp receptor antagonists | |
| IL245948B (en) | 5–ht4 indazole compounds as receptor agonists | |
| HRP20190141T1 (hr) | Oblik doziranja antagonista receptora progesterona | |
| ZA201601645B (en) | Bendamustine pharmaceutical compositions | |
| IL246091A0 (en) | Opioid antagonist formulations | |
| SI3079691T1 (sl) | Farmacevtski sestavek, ki vsebuje dantrolen kot rianodin receptor antagonist za olajšanje celjenja ran | |
| HK1216101A1 (zh) | 用作促性腺激素釋放激素受體拮抗劑的螺二氫吲哚衍生物 | |
| GB201304666D0 (en) | Dopamine receptor antagonist |